Trials in rare diseases: the need to think differently by Billingham, Lucinda et al.
INVITED SPEAKER PRESENTATION Open Access
Trials in rare diseases: the need to think
differently
Lucinda Billingham
1,2*, Kinga Malottki
1, Mark Pritchard
2, Neil Steven
2
From Clinical Trials Methodology Conference 2011
Bristol, UK. 4-5 October 2011
Background
In general, large-scale clinical trials are needed to make
definitive conclusions regarding changes in treatment
practice. This is because treatment effects are often
modest and large numbers of patients are needed to
detect such differences with sufficient power for robust
conclusions. Such trials are difficult and often impossi-
ble in rare diseases and their worth in this setting could
be questioned and this drives the need to consider a dif-
ferent approach.
Methods
A review is undertaken of methods that may be appro-
priate for making conclusions from clinical trials of
treatment in rare diseases. In particular, the practicalities
of applying a Bayesian strategy [1] are assessed by appli-
cation to a trial in Merkel cell carcinoma.
Results
I tm a yb ep o s s i b l et or u nat r a d i t i o n a lt r i a li nr a r ed i s -
eases by adapting logistical aspects in order to maximise
recruitment but alternative statistical approaches are
normally needed. In rare diseases, if the focus is on esti-
mation rather than hypothesis testing then important
information can be gleaned from small trials, with inter-
val estimates providing a measure of the uncertainty
inherent in small studies. Using a Bayesian approach to
trial design in the rare disease setting has been pro-
moted as this enables information gathered from rele-
vant previous studies to contribute to the estimation
process. Proposed methodology suggests incorporating
all levels of evidence, including case studies, into the
prior distribution with appropriate weighting to reflect
quality [1]. Practical application of this approach
highlights that the substantial effort in incorporating
lower levels of evidence may not be worth the gain in
information, especially when such information is prone
to bias.
Conclusions
Treatment decisions in rare diseases should be based on
evidence but the traditional approach to trials is difficult
and therefore there is a need to think differently. Small
trials focused on estimation rather than hypothesis test-
ing are worthwhile as they will reduce the uncertainty
about treatment effects. Incorporating prior knowledge
together with trial data using a Bayesian approach can
further reduce the uncertainty but the acceptability of
this approach is subject to the believability of the prior
information.
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